Investment analysts at Maxim Group initiated coverage on shares of Virios Therapeutics (NASDAQ:VIRI – Get Free Report) in a research report issued on Thursday, Benzinga reports. The firm set a “buy” rating and a $1.00 price target on the stock. Maxim Group’s target price suggests a potential upside of 301.61% from the stock’s current price.
Virios Therapeutics Stock Performance
VIRI stock opened at $0.25 on Thursday. Virios Therapeutics has a one year low of $0.16 and a one year high of $2.42. The firm’s fifty day moving average is $0.34 and its 200 day moving average is $0.44. The firm has a market cap of $4.80 million, a PE ratio of -0.92 and a beta of 1.62.
Virios Therapeutics (NASDAQ:VIRI – Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Research analysts predict that Virios Therapeutics will post -0.27 earnings per share for the current fiscal year.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
See Also
- Five stocks we like better than Virios Therapeutics
- Top Stocks Investing in 5G Technology
- Signet Jewelers Stock Poised for Rebound After Earnings Drop
- How to Invest in Insurance Companies: A Guide
- Airship AI Lands New Contract: Stock Soars 16% and More to Come
- How Can Investors Benefit From After-Hours Trading
- Restoration Hardware Stock: Should You Buy After Earnings Drop?
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
